Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.37 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765023 | 1.00 | EGFR (0.48) | EGFRFGFR4PIK3CAPIK3CDRPS6KA5 | |
| SCHEMBL30466525 | 0.84 | EGFR (0.47) | EGFRFGFR4PIK3CAPIK3CDRPS6KA5 | |
| SCHEMBL8874014 | 0.78 | EGFR (0.58) | EGFRFGFR4PIK3CAPIK3CDTDO2 | |
| SCHEMBL7920056 | 0.76 | EGFR (0.47) | EGFRFGFR4PIK3CAPIK3CDTDO2 | |
| SCHEMBL6364161 | 0.76 | EGFR (0.57) | EGFRFGFR4PIK3CAPIK3CD | |
| SCHEMBL4147243 | 0.74 | EGFR (0.60) | EGFRFGFR4PIK3CAPIK3CDTDO2 | |
| SCHEMBL24558650 | 0.73 | ALDH1A1 (0.50) | EGFRRPS6KA5ALDH1A1 | |
| SCHEMBL3320194 | 0.71 | PDE4A (0.47) | EGFRALDH1A1 | |
| SCHEMBL30460888 | 0.71 | EGFR (0.43) | EGFRFGFR4PIK3CAPIK3CDRPS6KA5 | |
| SCHEMBL2611072 | 0.71 | EGFR (0.43) | EGFRFGFR4PIK3CAPIK3CDTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195475-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | EGFR 55/4885FGFR4 797/4885PIK3CA 218/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | EGFR 55/4885FGFR4 797/4885PIK3CA 218/4885 |
| US-12195475-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | EGFR 55/4885FGFR4 797/4885PIK3CA 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.